Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

AUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its addition to the Russell 2000^® and Russell 3000^® Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution. Shattuck’s addition will be effective today when the U.S. equity markets open.